One biologic comes out on top in psoriatic arthritis trial

It's the first direct comparison of adalimumab and ixekizumab for the condition

The first head-to-head trial of two biologics for psoriatic arthritis suggests that, while adalimumab and ixekizumab are both effective, ixekizumab may have the edge in patients with active skin disease.